Decreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinoma

被引:1
作者
Chu, Xia [1 ,2 ]
Zhao, Po [2 ]
Lv, Yali [2 ]
Liu, Lin [2 ]
机构
[1] PLA, Hosp 153, Dept Pathol, Zhengzhou 450042, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Dept Pathol, Beijing 100853, Peoples R China
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY | 2015年 / 8卷 / 01期
关键词
Cholangiocarcinoma; TFPI-2; CD133; immunohistochemistry; prognosis; FACTOR PATHWAY INHIBITOR-2; TUMOR-SUPPRESSOR GENE; PROMOTER HYPERMETHYLATION; MATRIX METALLOPROTEINASES; CERVICAL-CARCINOMA; HEMATOPOIETIC STEM; IN-VITRO; CELL; IDENTIFICATION; INVASION;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Recent findings suggest decreasing TFPI-2 expression plays a significant role in inhibiting cell migration and tumor invasion. The clinicopathological significance of the expression of TFPI-2 and its possible correlation with the expression of CD133 in cholangiocarcinoma remains to be solved. Methods: We investigated if TFPI-2 was involved in the clinicopathological significance of cholangiocarcinoma. An immunohistochemical method was used to detect 218 cases of cholangiocarcinoma, 30 para-neoplastic and 20 normal bile ducts for their expression status of TFPI-2 and CD133, and then the results were analyzed with the patient's age, sex, tumor site and the histological grade, clinical stage as well as overall mean survival time. Results: Compared with the para-neoplastic and normal cholangiocytes, the expression of TFPI-2 was obviously decreased while the expression of CD133 in carcinoma cells was increased. Carcinomas with low expression of TFPI-2 were significantly corresponding to the tumor site (P = 0.006), size (P = 0.005), histological grade (P = 0.0001) and clinical stage (P = 0.0001), but not to the age (P = 0.066) and sex (P = 0.411), respectively. By Kaplan-Meier survival analysis, the low expression of TFPI-2 was significantly correlative with the overall survival time (P = 0.0001). Further, the expression of TFPI-2 was found inversely correlative with the expression of CD133 (g = -0.3876, P < 0.0001). Conclusions: Our finding suggests that the decreased expression of TFPI-2 may play an important role in the carcinogenesis and progression, and may become a new adjunct marker in the diagnosis and prognosis in cholangiocarcinoma. The expression of TFPI-2 may be inversely correlative with the expression of CD133.
引用
收藏
页码:328 / 336
页数:9
相关论文
共 35 条
  • [1] Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours
    Berman, DM
    Karhadkar, SS
    Maitra, A
    de Oca, RM
    Gerstenblith, MR
    Briggs, K
    Parker, AR
    Shimada, Y
    Eshleman, JR
    Watkins, DN
    Beachy, PA
    [J]. NATURE, 2003, 425 (6960) : 846 - 851
  • [2] Structure, function and biology of tissue factor pathway inhibitor-2
    Chand, HS
    Foster, DC
    Kisiel, W
    [J]. THROMBOSIS AND HAEMOSTASIS, 2005, 94 (06) : 1122 - 1130
  • [3] Structure-function analysis of the reactive site in the first Kunitz-type domain of human tissue factor pathway inhibitor-2
    Chand, HS
    Schmidt, AE
    Bajaj, SP
    Kisiel, W
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (17) : 17500 - 17507
  • [4] CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma
    Fan, Linni
    He, Furong
    Liu, Hongxiang
    Zhu, Jin
    Liu, Yixiong
    Yin, Zhiyong
    Wang, Lu
    Guo, Ying
    Wang, Zhe
    Yan, Qingguo
    Huang, Gaosheng
    [J]. BMC CANCER, 2011, 11
  • [5] Knockdown of TFPI-2 promotes migration and invasion of glioma cells
    Gessler, Florian
    Voss, Valerie
    Seifert, Volker
    Gerlach, Ruediger
    Koegel, Donat
    [J]. NEUROSCIENCE LETTERS, 2011, 497 (01) : 49 - 54
  • [6] A. spotlight on cholangiocarcinoma
    Gores, GJ
    [J]. GASTROENTEROLOGY, 2003, 125 (05) : 1536 - 1538
  • [7] Hao XP, 2000, CANCER RES, V60, P18
  • [8] Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis
    Herman, MP
    Sukhova, GK
    Kisiel, W
    Foster, D
    Kehry, MR
    Libby, P
    Schönbeck, U
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (09) : 1117 - 1126
  • [9] Heron DE, 2003, AM J CLIN ONCOL-CANC, V26, P422
  • [10] Transcriptional silencing of the TFPI-2 gene by promoter hypermethylation in choriocarcinoma cells
    Hubé, F
    Reverdiau, P
    Iochmann, S
    Rollin, J
    Cherpi-Antar, C
    Gruel, Y
    [J]. BIOLOGICAL CHEMISTRY, 2003, 384 (07) : 1029 - 1034